Clinical Trial Update: A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ASP2215 (gilteritinib) in combination with induction and consolidation chemotherapy in newly diagnosed acute myeloid leukemia has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ASP2215 (gilteritinib) (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED